Year: 2026

On 30 April 2026, the Annual General Meeting of Shareholders of APRANGA, APB (code 121933274, registered address: Ukmergės str. 362, Vilnius, Lithuania) decided to allocate the Company’s profit for the year 2025 and to pay out EUR 0.27 dividend per share. Dividends will be paid to the shareholders who at the end of the tenth business day following the day of the Annual General Meeting that adopted a decision on dividend payment, i.e. on 15 May 2026 are shareholders of APRANGA, APB. The Ex-Date or the first day from when on regulated market (i.e. on stock exchange) with settlement period of T+2 acquired shares of APRANGA, APB do not entitle to the dividends for the year 2025 is 14 May 2026.  Dividends will be paid out starting from 28 May 2026 in the following order: to the shareholders, whose APRANGA, APB shares are accounted by a financial...

Oslo, Norway, 4 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation of its first quarter 2026 results on Thursday, 7 May 2026. The presentation will be available via a live webcast on www.zelluna.com at 09:00 CEST on Thursday, 7 May 2026. The webcast recording will remain available on the company’s website after the event, and participants will be able to submit questions during the presentation. The quarterly report and presentation materials will be published on the company’s website at 07:00 CEST on the same day. For further information, please visit www.zelluna.com or contact: Namir Hassan, CEOEmail: namir.hassan@zelluna.comPhone: +44 7720 687608 Geir Christian Melen, CFOEmail: geir.christian.melen@zelluna.comPhone:...

ANNOUNCEMENT NO. 307 4 May 2026 Adjustment of accounting estimates contributes to an upgrade of revenue and operating profit guidance To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services. This has had a positive one-off effect on sales of instruments and EBITDA of DKK 15.1 million and means that a larger share of revenue will be recognised in the sale of instruments going forward. Based on this, the Company now expects revenue for the 2025/26 financial year in the DKK 505-525 million range, up from DKK 490-520 million in the most recent guidance, and EBITDA in the DKK 275-290 million range, up from DKK 260-285 million previously.  ChemoMetec’s trading statement for Q3 2025/26 is scheduled to be released on Wednesday, 6 May 2026. Additional...

– 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma – – Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology – – Highly heterogeneous patient population for whom available options are extremely limited included patients ineligible for chemotherapy as well as patients who had received up to four prior lines of chemotherapy – – Streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed for seamless integration into standard GI endoscopy workflow – – Results shared in oral presentation at DDW 2026, the...

Press release – Paris, May 4th, 2026  Linda Li is appointed as President and CEO North America SMCP is pleased to announce the appointment of Linda Li as President and CEO for North America. She will succeed Ida Simonsen, who has decided to pursue new opportunities, and whom the Group warmly thanks for her contribution to the development of its North American operations over the past years. Linda Li will join the Group’s Executive Committee. SMCP intends to continue rolling out its strategy in North America around several key pillars: controlled expansion of its network, continued implementation of its full-price policy, and acceleration of its omnichannel approach to strengthening its brands’ desirability. Isabelle Guichot, CEO of SMCP, said: “We are delighted to welcome Linda Li to SMCP as President and CEO for North America. Her...

New partnership helps political advertisers activate influencer-aligned audience segments as one in five Americans increasingly turn to social creators for news NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) — Nexxen (NASDAQ: NEXN), the advertising technology platform powered by unique data and media, today announced an exclusive partnership with fandom intelligence provider ADvolution to make audience segments that amplify influencer reach available in Nexxen’s demand-side platform (“DSP”), Nexxen DSP. Fandom communities are where opinions form, narratives spread and cultural cues gain momentum. That influence is increasingly measurable: according to Pew Research Center, one in five Americans regularly gets news from influencers on social media, rising to 37% among adults ages 18 to 29. As both programmatic execution and influencer marketing...

ORION CORPORATION MANAGERS’ TRANSACTIONS 4 MAY 2026 at 16.00 EEST         Orion Corporation: Managers’ transactions – Hilpi Rautelin Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Hilpi RautelinPosition: Member of the Board/Deputy member Issuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 154795/4/4 ____________________________________________Transaction date: 2026-04-30Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)Instrument type: SHAREISIN: FI0009014377Nature of transaction:...